>
City by City Being Eaten Alive by Third World Immigration in America
"Doomsday": U.S. Military Planning To Survive 90 Days Without Power Grid
Former DOGE Staffers Hacked Into Anthropic's Internal Systems In 12 Hours...
MASSIVE CRASH at the opening in Brazil
Modular phone promises total privacy at the flick of a switch
Genetically Engineered War Dogs for 134 Pound Cyborg Dire Wolves Now – Later 600 Pound Wolves
They're Quietly REPLACING Our Food With THIS… And Nobody Is Talking About It!
Chicago Opens First "Teacher-Free" AI School as Global Push Accelerates
Solar Panels Are Doing Something Nobody Expected
DeLorean climbs skyward to race electric flying cars
Atari's 800XL returns with a keyboard, cartridges and BASIC
Bioinspired robot airdrops into remote waters via morphing wing-sail
Anduril interceptor adapts to emerging threats via swappable stages

Two adults with leukaemia have been in remission since 2010 after Car-T therapy.
It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body's immune system to attack tumours.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: "Based on these results, we can conclude that Car-T cells can cure leukaemia.
"These cells continued to demonstrate tumour-killing characteristics."
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: "I knew the doctors weren't sure but I was pretty convinced that I was done with cancer."
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.